Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study
In this real-world comparative effectiveness study of patients with COPD initiating BGF or MITT, BGF was associated with lower all-cause mortality and severe cardiopulmonary event risk versus MITT after accounting for between-group differences in baseline sociodemographic and clinical characteristics. This study supports the benefits of BGF over MITT and the need to consider proactive use of SITTs in COPD management.
Authors
- Kirsty Rhodes (ORCID: https://orcid.org/0000-0002-8568-4979)
- Hana Müllerová (ORCID: https://orcid.org/0000-0002-0949-0101)
- Eleni Rapsomaniki (ORCID: https://orcid.org/0000-0003-4898-6078)
- Nathaniel M. Hawkins (ORCID: https://orcid.org/0000-0003-1286-2014)
- Antonio Anzueto (ORCID: https://orcid.org/0000-0002-7007-588X)
- Claus Franz Vogelmeier (ORCID: https://orcid.org/0000-0002-9798-2527)
- Jonathan C. Marshall (ORCID: https://orcid.org/0000-0003-0758-9658)
- Michael Pollack (ORCID: https://orcid.org/0000-0001-7351-3059)
Institutions
- AstraZeneca (United Kingdom) (GB)
- University of British Columbia (CA)
- The University of Texas at San Antonio Health Science Center (US)
- AstraZeneca (France) (FR)
- AstraZeneca (Switzerland) (CH)
- German Center for Lung Research (DE)
- South Texas Veterans Health Care System (US)
Publication Details
- Journal
- The American Journal of Medicine
- Published
- 2024-11-18
- DOI
- https://doi.org/10.1016/j.amjmed.2024.11.007
- Citations
- 8
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 3.35
Funders
- AstraZeneca